If you live with knee, hip, or back pain and have been researching stem cell therapy, you may have come across a newer term: MUSE cells. MUSE cells are a unique population of stem cells being studied for their potential role in tissue repair.
How do they compare to the mesenchymal stem cells (MSCs) commonly used in regenerative medicine, and does the rise of MUSE cell research mean MSCs are becoming outdated? In this guide to MUSE cells vs stem cells, we explain what the science shows today.
Understanding Mesenchymal Stem Cells (MSCs)
What are the different types of stem cells? Researchers broadly group them into embryonic stem cells, induced pluripotent stem cells (iPSCs), and adult stem cells. Among adult stem cells, a common comparison is mesenchymal stem cells vs hematopoietic stem cell types: hematopoietic cells form blood and immune cells, while MSCs are linked to connective tissue repair.
Mesenchymal stem/stromal cells, commonly called MSCs, are among the most widely studied types of adult stem cells in regenerative medicine. These multipotent cells can develop into a limited range of cell types and are found in several tissues. Sources include bone marrow, adipose (fat) tissue, and perinatal tissues such as Wharton’s Jelly, the connective tissue within the umbilical cord.
MSCs have attracted scientific attention because they interact with surrounding cells and influence inflammation and repair. One important characteristic is their ability to release signaling molecules, including growth factors, cytokines, and extracellular vesicles such as exosomes.
These signals may help regulate inflammation and support tissue repair. This cell-to-cell communication is known as paracrine signaling.
This has fueled interest in MSCs for orthopedic conditions, musculoskeletal injuries, and immune-related disorders. However, clinical evidence varies considerably by condition, cell source, and product preparation, and many proposed uses remain investigational.
What Are MUSE Cells?
MUSE stands for Multilineage-differentiating Stress-Enduring cells. They were first described by a team led by Professor Mari Dezawa in Japan. They occur naturally in certain adult and perinatal tissues, including bone marrow, adipose tissue, and umbilical cord tissue.
Perhaps the most interesting distinction is that MUSE cells can exist within the broader population of cells classified as MSCs. So are MUSE cells stem cells in their own right? They are, but they are not necessarily an entirely separate source of stem cells. Instead, MUSE cells represent a specialized subpopulation that researchers commonly identify using a cell-surface marker called SSEA-3, often alongside other markers.
Laboratory and animal studies suggest several unusual properties that set MUSE cells apart and make the MUSE cells vs stem cells comparison worth a closer look:
– They can withstand stressful cellular environments.
– They may differentiate into a broader variety of cell types.
– They appear to recognize certain signals released by damaged tissue.
– They may migrate toward areas of injury.
– They show biological characteristics associated with immune regulation and tissue repair.
Still, laboratory results are not the same as proven clinical outcomes in patients.
MUSE Cells vs MSCs: Five Key Differences
When researchers compare MUSE cells vs mesenchymal stem cells, the differences come down to composition, differentiation, injury response, repair mechanism, and the maturity of the clinical research.
1. MUSE cells are a specialized population within MSC preparations. Traditional MSC preparations contain a mixed (heterogeneous) population of cells. MUSE cells usually make up a small share of that population, and that share varies by tissue source and processing methods.
This leads to an important distinction: an MSC preparation may contain MUSE cells without being a purified or enriched MUSE cell product. The presence, quantity, and biological activity of MUSE cells cannot be assumed without appropriate laboratory testing.
2. MUSE cells demonstrate broader differentiation potential. MSCs are generally classified as multipotent. In the lab, they typically become bone, cartilage, or fat cells.
MUSE cells have shown broader potential in laboratory studies, expressing characteristics of cell types from all three embryonic germ layers. This is often described as pluripotent-like behavior. Still, this does not establish that MUSE cells can reliably regenerate every type of damaged human tissue after treatment.
3. MUSE cells may recognize signals released by injured tissue. When tissue is damaged, surrounding cells release biological signals, including one called sphingosine-1-phosphate (S1P). Preclinical research suggests that MUSE cells respond to S1P signaling and migrate toward damaged tissue, a process often described as injury homing.
Conventional MSCs also migrate and signal, but through different mechanisms. Additional human studies are needed to determine how consistently MUSE cell homing occurs and whether it produces better clinical outcomes.
4. MUSE cells may participate in tissue replacement. MSC research has focused mainly on paracrine signaling, while MUSE cell research explores direct participation in replacing damaged cells.
In certain preclinical studies, MUSE cells integrated into injured tissues and developed characteristics of surrounding cell types. Nevertheless, demonstrating cellular differentiation in a research setting is not the same as proving functional tissue restoration in patients.
5. The clinical research is at different stages. MSCs have been investigated in a wide range of human studies over several decades. MUSE cells represent a newer, more specialized research area with a much smaller body of human clinical evidence.
For example, a randomized clinical trial in Japan investigated an experimental MUSE cell-based product called CL2020 in patients recovering from ischemic stroke. The study found encouraging signals but also documented adverse reactions and the limits of a small sample. These results support continued research, but they do not prove that MUSE cells are superior to MSCs across unrelated conditions.
MUSE Cells vs Stem Cells: Is Newer Always Better?
At present, there is not enough high-quality comparative clinical evidence to conclude that MUSE cell treatments are more effective than conventional MSC preparations.
Although MUSE cells have distinctive biological properties, treatment effectiveness depends on much more than a cell’s classification. Several factors play a role:
– The tissue source determines which cells a product contains.
– Isolation and processing methods affect cell quality.
– Viability testing shows whether the cells are alive and biologically active.
– The condition being treated shapes what results are realistic.
– The method of administration influences where the cells go.
– The dose and composition vary from product to product.
– The strength of clinical evidence differs from one condition to another.
Because of these factors, any fair comparison of MUSE cells vs stem cells should focus on specific products and clinical outcomes, not simply on which cell type sounds newer or more advanced. If you are weighing options more broadly, our guide to how PRP, stem cells, and exosomes compare explains other regenerative approaches.
Are MUSE Cells Already Present in Traditional MSC Therapies?
Potentially, yes. Because MUSE cells can exist within broader MSC populations, some MSC preparations may naturally contain cells with MUSE characteristics. However, the concentration can vary, and not all commercially available products have been tested for MUSE cell markers.
Researchers have reported MUSE cells in umbilical cord MSCs, but the data are still limited. An MSC product derived from Wharton’s Jelly should not automatically be described as containing a verified concentration of MUSE cells. That determination requires appropriate laboratory testing.
An enriched MUSE cell preparation and a conventional MSC preparation are not interchangeable simply because they come from similar tissues.
What MUSE Cell Research Could Mean for Joint and Orthopedic Care
For many patients with joint pain, the MUSE cells vs stem cells question comes down to orthopedic care. Researchers continue to study MSCs and other cellular technologies for cartilage health, tendon injuries, inflammation, and joint conditions, including stem cell therapy for knee arthritis.
MUSE cell research raises worthwhile questions about more targeted repair of damaged musculoskeletal tissue. However, evidence from neurological or cardiovascular studies cannot automatically be applied to osteoarthritis, meniscus injuries, rotator cuff damage, or degenerative spine conditions. Today, direct evidence of better orthopedic outcomes from MUSE cells remains insufficient, and more controlled studies are needed.
The Future of Regenerative Medicine: Why Cell Quality Still Matters
As cellular technologies evolve, patients may encounter increasingly sophisticated terminology, such as MUSE cells in umbilical cord MSCs, and marketing that compares different types of stem cells. Cell identity, manufacturing quality, donor screening, product characterization, and regulatory compliance all matter. So does an individualized medical evaluation that considers your symptoms, medical history, imaging findings, and goals.
Neither MSCs nor MUSE cells should be assumed to offer a guaranteed solution for any medical condition. In the United States, MUSE cell products and MSC products intended for orthopedic treatment have not received FDA approval for those uses.
When it comes to MUSE cells vs stem cells, the takeaway is clear. The emergence of MUSE cells does not mean traditional MSCs are obsolete. It means researchers are continuing to uncover new layers of complexity within regenerative medicine.
At LeHeal Biogenix, we believe patients benefit from understanding both the potential and the limitations of emerging science. Our physician-led approach uses MSCs from ethically sourced Wharton’s Jelly and emphasizes individualized evaluations, education, and informed conversations about care options.
Explore Regenerative Medicine With LeHeal Biogenix
If you have questions about MUSE cells vs stem cells or whether regenerative medicine may fit your needs, the LeHeal care team is here to help. Schedule a consultation at our Tampa clinic to discuss your medical history, diagnostic findings, and non-surgical options that may help you get back to the activities you love. We also welcome patients from Brandon and Lutz.
Medically reviewed.
Medical note: This article is intended for educational purposes. MUSE cell therapies and MSC products intended to treat orthopedic conditions remain investigational and are not FDA-approved for those uses. The information provided does not establish the safety or effectiveness of any particular cellular product.
This physician performs one or more stem cell therapies that have not yet been approved by the United States Food and Drug Administration. You are encouraged to consult with your primary care provider prior to undergoing a stem cell therapy.
FAQ
MUSE stem cells vs MSCs: what is the main difference?
MSCs are a broad, mixed population that is thought to work mainly through paracrine signaling. MUSE cells are a smaller subpopulation within MSCs that, in preclinical studies, show broader differentiation potential and homing toward injured tissue.
Are MUSE cells safer than iPSCs?
Induced pluripotent stem cells (iPSCs) are lab-reprogrammed cells that carry a known risk of forming tumors. Animal studies have reported that MUSE cells did not form tumors, but human safety data remain limited, and the CL2020 stroke trial documented adverse reactions.
Are MUSE cell and MSC therapies FDA-approved?
No. In the United States, MUSE cell products and MSC products have not been approved by the FDA for orthopedic conditions. These uses remain investigational.